Clinical Trial Update: Study Evaluating the Safety and Tolerability of SCA-136 in Healthy Japanese Male Subjects [Phase 1]

View source ↗

Summary

Wyeth (now a Pfizer subsidiary) completed a Phase 1 study evaluating the safety and tolerability of SCA-136 in healthy Japanese male subjects; schizophrenia is …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• SCA-136

Snippet

Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer | Conditions: Schizophrenia | Phase 1 | Status: COMPLETED